The safety of double- and triple-drug community mass drug administration for lymphatic filariasis: A multicenter, open-label, cluster-randomized study

Keyphrases

• Lymphatic Filariasis 100%
• Mass Drug Administration 100%
• Diethylcarbamazine 100%
• Cluster-randomized Study 100%
• Albendazole 85%
• Ivermectin 51%
• Adverse Events 33%
• Albendazole Therapy 14%
• Serious Adverse Events 11%
• Adverse Event Rates 7%
• Indonesia 3%
• Adjusted Odds Ratio 3%
• Abdominal Pain 3%
• Nausea 3%
• India 3%
• Headache 3%
• Elephantiasis 3%
• Filariasis 3%
• Fever 3%
• Community-based Study 3%
• Antifilarial 3%
• Global Programme to Eliminate Lymphatic Filariasis 3%
• Filarial Infection 3%
• Drug Treatment 3%
• Elimination Program 3%
• Severe Adverse Events 3%
• Single Oral Dose 3%
• Active Follow-up 3%
• Large Community 3%
• Administration Regimen 3%
• Two-drug Combination 3%
• Medical Team 3%
• Papua New Guinea 3%
• Fiji 3%
• Treatment Assignment 3%
• Haiti 3%
• Event Severity 3%
• Adverse Event Data 3%
• Endemic Settings 3%
• Event Frequency 3%
• Dizziness 3%
• Endemic Population 3%
• Well Tolerated 3%
• Fixed Dose 3%
• Microfilaremia 3%
• Registration number 3%

Medicine and Dentistry

• Lymphatic Filariasis 100%
• Drug Administration 100%
• Diethylcarbamazine 100%
• Albendazole 100%
• Adverse Event 55%
• Ivermectin 51%
• Filariasis 7%
• Abdominal Pain 3%
• Drug Therapy 3%
• Headache 3%
• Elephantiasis 3%
• Nausea 3%
• Study Participant 3%
• Microfilariasis 3%
• Dizziness 3%
• Single Drug Dose 3%
• Combination Drug 3%
• Odds Ratio 3%
• Oral 3%

Pharmacology, Toxicology and Pharmaceutical Science

• Drug Administration 100%
• Lymphatic Filariasis 100%
• Diethylcarbamazine 100%
• Albendazole 100%
• Adverse Event 55%
• Ivermectin 51%
• Elimination 7%
• Filariasis 7%
• Abdominal Pain 3%
• Nausea 3%
• Pharmacotherapy 3%
• Headache 3%
• Microfilariasis 3%
• Combination Drug 3%
• Dizziness 3%
• Elephantiasis 3%